CRSP Q2 EPS Estimate Reduced by Brookline Capital Management

CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Analysts at Brookline Capital Management cut their Q2 2025 earnings estimates for shares of CRISPR Therapeutics in a research report issued on Tuesday, May 6th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($1.23) per share for the quarter, down […]

Leave a Reply

Your email address will not be published.

Previous post Q2 Earnings Forecast for Informatica Issued By DA Davidson
Next post Zacks Research Weighs in on HEICO’s Q2 Earnings (NYSE:HEI)